Key Points
- Only one absolute contraindication: known hypersensitivity to quetiapine or any formulation excipients (anaphylaxis has been reported)
- Elderly with dementia-related psychosis: not approved for this use; associated with ~1.6–1.7x increased risk of death vs placebo (FDA boxed warning)
- QTc prolongation: avoid in congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesaemia, and with concurrent QTc-prolonging drugs
- Pregnancy: limited human safety data; neonatal withdrawal symptoms reported; use only if benefit clearly outweighs risk
- Breastfeeding: not recommended
Absolute Contraindication
- Hypersensitivity to quetiapine or any excipient in the formulation; anaphylactic reactions have been reported
Major Warnings (Relative/Clinical Contraindications)
Elderly Patients with Dementia-Related Psychosis
- Avoid — antipsychotics increase mortality approximately 1.6–1.7x compared to placebo in this population (the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group)
- However, deaths were primarily cardiovascular or infectious in nature
- Not an approved indication
QTc Prolongation / Cardiac Risk
Avoid quetiapine (or use with extreme caution) in people with the following risk factors:
- Congenital long QT syndrome
- History of cardiac arrhythmia, including bradycardia
- Concomitant use of other QTc-prolonging drugs: Class IA antiarrhythmics (quinidine, procainamide), Class III antiarrhythmics (amiodarone, sotalol), Antimicrobials (macrolides, fluoroquinolones), methadone, TCAs, other antipsychotics
- Hypokalemia or hypomagnesaemia
- Congestive heart failure or cardiac hypertrophy
Drug–Drug Interaction–Related “Functional Contraindications"
- Elderly and those on CYP inhibitors (e.g., fluvoxamine, some SSRIs, clozapine) may have markedly increased serum levels and toxicity; lower doses should be considered
- Quetiapine is sensitive to CYP3A enzyme induction
Suicidality
- Increased risk of suicidal thoughts/behaviour in adolescents and young adults, particularly when used as adjunctive antidepressant therapy; requires close monitoring
Situations Requiring Significant Caution
| Clinical Situation | Concern |
|---|---|
| Diabetes mellitus | Risk of hyperglycaemia and hyperosmolar coma; monitor glucose |
| Primary insomnia (off-label) | Scant evidence |
| Seizure history / Alzheimer's dementia | Lowers seizure threshold (0.5% incidence in trials) |
| Hepatic impairment | Reduced clearance; lower starting doses required |
| Urinary retention / prostatic hypertrophy | Anticholinergic effects may worsen voiding |
| Narrow-angle glaucoma | Increased intraocular pressure risk |
| Aspiration risk / dysphagia | Oesophageal dysmotility reported; risk of aspiration pneumonia |
| Pregnancy | Limited safety data; neonatal withdrawal symptoms reported |
| Breastfeeding | Not recommended |
| Metabolic syndrome / obesity | Causes weight gain, dyslipidaemia, and hyperglycaemia even at low doses |
| CNS depressants / alcohol | Additive sedation and hypotension |
Note on dementia with Lewy bodies / Parkinson's disease: Quetiapine is sometimes preferred among antipsychotics in this context due to its lower extrapyramidal burden, but the general dementia mortality warning still applies and careful risk-benefit assessment is required.
See sources cited
- [PDF] SEROQUEL® (quetiapine) tablets, for oral use - accessdata.fda.gov
- Boxed Warning - accessdata.fda.gov
- [PDF] Quetiapine Fumarate Extended-Release Tablets
- Quetiapine - StatPearls - NCBI Bookshelf - NIH
- [PDF] quetiapine extended-release tablets
- Quetiapine for primary insomnia: Consider the risks | Cleveland Clinic Journal of Medicine
- [PDF] In an Emergency Setting, What Is the Best Intramuscular ...
Evidence Validator
Heidi Clinical Team1 Contribution
Dr. Jun-Ting Yeung
General Medicine•AU

